Navigation Links
Andrew P. Mandell - Mr. Diabetes(R) to Sit On ProtoKinetix Advisory Board
Date:1/15/2010

MADEIRA BEACH, Fla., Jan. 15 /PRNewswire/ -- Andrew P. Mandell – Mr. Diabetes®, Executive Director of Defeat Diabetes Foundation and diabetes advocate announced today that he will be sitting on the ProtoKinetix (PKTX) Advisory Board.  ProtoKinetix, Inc. is a biotechnology company that has developed and patented a family of synthetic anti-aging glycoproteins (AAGP™) for medicine and the biotechnology and cosmetic industries.

"I'm really excited about their technology and it's potential to offer the first truly viable long term treatment for diabetes," said Mandell. "The Protokinetix's research team has made remarkable progress in the harvesting and preservation of stem cells for islet transplantation for diabetes treatments," he continued.

"In addition to the potential treatments for diabetes, AAGP™ also shows great promise in many other medical applications. I'm really looking forward to contributing where I can to support their work," Mandell concluded.

Defeat Diabetes Foundation

Defeat Diabetes Foundation is a 501(c)(3) nonprofit  whose mission is the prevention, early identification and effective self management of diabetes.

DDF has awareness and interactive programs in all 50 states to provide critical information and education programs with a focus on diabetes, nutrition and physical fitness. Their public information programs include the KIDD™ Project which has provided millions of Free Defeat Diabetes® Screening Test brochures to schools in all 50 states, the DAN Project, a Public Service Announcements program and the Martial Arts Defeat Diabetes® Community Action Project (MADDCAP™) a historic health curriculum for martial arts schools and their students.

For information on diabetes, to take the free screening test or obtain additional information visit: www.DefeatDiabetes.org

For information on ProtoKinetix visit the website at: www.protokinetix.com

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission.

SOURCE Defeat Diabetes Foundation

RELATED LINKS
http://www.defeatdiabetes.org/
http://www.protokinetix.com/

'/>"/>

SOURCE Defeat Diabetes Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Vical Names Andrew de Guttadauro Vice President, Corporate Development
2. MacAndrews & Forbes Names Barry F. Schwartz as Executive Vice Chairman
3. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
4. 5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
5. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
6. Algeta Appoints Andrew Kay as President and Chief Executive Officer
7. Andrew Chisholm Appointed Vice President, Sales and Corporate Accounts at Accumetrics
8. Veridiam Appoints Andrew Gale as Chief Executive Officer
9. BioNeutral Groups CEO, Stephen Browand and Chief Scientist, Dr. Andrew Kielbania to Appear on WVOX 1460 AM In Focus Radio Show Hosted by Dr. Dan Miller
10. Jonathan Moreno and Andrew Light Speak About Biotechnology and Global Warming at the National Press Club
11. ProtoKinetix Partners with OTC Financial Network to Increase Shareholder Base
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2020)... (PRWEB) , ... July 29, 2020 , ... ... reliable, solid-state radar transmitter systems that can be configured to drive Klystrons, TWTs, ... controller that can drive one or two switches in a push-pull configuration; yielding ...
(Date:7/31/2020)... ... July 29, 2020 , ... eSource has long been touted as the ... the history of eSource, the reasons it did not take off as quickly as ... source, the industry is moving towards capturing data electronically for clinical trials and then ...
(Date:7/22/2020)... ... July 22, 2020 , ... Join experts from ... Sr. Manager Regulatory Solutions, in a one hour live webinar on Thursday, ... body in China for drugs and medical devices. Specifically, for medical devices, the NMPA ...
(Date:7/18/2020)... ... July 16, 2020 , ... Medial EarlySign , a ... prevention of high-burden diseases, and Centric Consulting, a business and technology consulting firm, ... existing data in order to identify and prioritize patients for care. , Combining ...
Breaking Biology Technology:
(Date:8/5/2020)... ... ... Regenative Labs has received approval from the Centers for Medicare & Medicaid Services ... jelly allografts to be assigned a Q code and be approved for application directly ... allograft product to be recognized as a 361 HCT/P by CMS regulated under 21CFR ...
(Date:7/31/2020)... SAN FRANCISCO (PRWEB) , ... July 30, 2020 ... ... Therapeutics’ maturing prescription digital therapeutics product portfolio with a near term focus on ... diverse biotech and pharma commercialization experience across multiple therapeutic areas and classes. As ...
(Date:7/18/2020)... , ... July 17, 2020 , ... Commercial launch readiness ... pharma’s ability to discover a COVID cure or vaccine, the global economic downturn will ... price pressure is not going away and capturing full value from every product launch ...
Breaking Biology News(10 mins):